QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:APVO

Aptevo Therapeutics (APVO) Stock Forecast, Price & News

$1.56
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$1.51
$1.61
50-Day Range
$1.56
$2.08
52-Week Range
$1.51
$7.20
Volume
73,654 shs
Average Volume
66,690 shs
Market Capitalization
$11.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Aptevo Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
728.0% Upside
$13.00 Price Target
Short Interest
Healthy
0.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.24) to ($4.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

Medical Sector

1729th out of 1,980 stocks

Pharmaceutical Preparations Industry

869th out of 978 stocks


APVO stock logo

About Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Stock News Headlines

AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
Aptevo Therapeutics (NASDAQ:APVO) Upgraded at StockNews.com
Short Volatility Alert: Aptevo Therapeutic
APVO Aptevo Therapeutics Inc.
See More Headlines

APVO Price History

APVO Company Calendar

Last Earnings
5/11/2023
Today
6/01/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
Employees
54
Year Founded
2016

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+729.5%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$8.03 million
Pretax Margin
225.24%

Debt

Sales & Book Value

Annual Sales
$3.11 million
Book Value
$3.19 per share

Miscellaneous

Free Float
7,020,000
Market Cap
$11.43 million
Optionable
Optionable
Beta
5.33

Social Links


Key Executives

  • Marvin L. White
    President, Chief Executive Officer & Director
  • Jeffrey G. Lamothe
    Chief Operating Officer & Executive Vice President
  • Daphne L. Taylor
    Chief Financial Officer & Senior Vice President
  • Dirk Huebner
    Chief Medical Officer
  • Miriam Weber Miller
    Investor Relations Contact













APVO Stock - Frequently Asked Questions

What is Aptevo Therapeutics' stock price forecast for 2023?

0 equities research analysts have issued twelve-month price targets for Aptevo Therapeutics' stock. Their APVO share price forecasts range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next year. This suggests a possible upside of 729.5% from the stock's current price.
View analysts price targets for APVO
or view top-rated stocks among Wall Street analysts.

How have APVO shares performed in 2023?

Aptevo Therapeutics' stock was trading at $2.32 at the start of the year. Since then, APVO stock has decreased by 32.4% and is now trading at $1.5673.
View the best growth stocks for 2023 here
.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 71,000 shares, a drop of 47.6% from the April 30th total of 135,500 shares. Based on an average daily volume of 53,100 shares, the days-to-cover ratio is currently 1.3 days.
View Aptevo Therapeutics' Short Interest
.

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our APVO earnings forecast
.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) released its earnings results on Thursday, May, 11th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.19) by $1.45.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.76%).
View institutional ownership trends
.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $1.57.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $11.43 million and generates $3.11 million in revenue each year.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503.

This page (NASDAQ:APVO) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -